(Q37675283)

21 August 2017

1 reference

title

The second Geneva Consensus: Recommendations for novel live TB vaccines (English)

1 reference

21 August 2017

K B Walker

1

1 reference

21 August 2017

M J Brennan

2

1 reference

21 August 2017

M M Ho

3

1 reference

21 August 2017

J Eskola

4

1 reference

21 August 2017

G Thiry

5

1 reference

21 August 2017

J Sadoff

6

1 reference

21 August 2017

R Dobbelaer

7

1 reference

21 August 2017

L Grode

8

1 reference

21 August 2017

M A Liu

9

1 reference

21 August 2017

U Fruth

10

1 reference

21 August 2017

P H Lambert

11

1 reference

21 August 2017

language of work or name

English

0 references

publication date

20 January 2010

1 reference

21 August 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 August 2017

volume

28

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

2259-2270

1 reference

Tuberculosis vaccine research: the impact of immunology

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Eradication of tuberculosis by 2050 impossible without new vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

TB vaccines: current status and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Comparative genomics of BCG vaccines by whole-genome DNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

A historical and molecular phylogeny of BCG strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Genome plasticity of BCG and impact on vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

A new evolutionary scenario for the Mycobacterium tuberculosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Live tuberculosis vaccines based onphoPmutants: a step towards clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Tuberculosis: from genome to vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

The ‘experimental stable’ of the BCG vaccine: safety, efficacy, proof, and standards, 1921–1933

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

BCG vaccination and WHO's global strategy for tuberculosis control 1948-1983.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Multiuse biopharmaceutical manufacturing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Animal models for experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Retracted: Analysis of Mycobacterium tuberculosis-Specific CD8 T-Cells in Patients with Active Tuberculosis and in Individuals with Latent Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

PhoP, a key player in Mycobacterium tuberculosis virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

Development of new tuberculosis vaccines: a global perspective on regulatory issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.083

10.1016/J.VACCINE.2009.12.083

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference